bioAffinity (BIAF) 10-Q2024 Q1 Quarterly report

Filed: 15 May 24, 10:53am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: agent, agreed, alternative, anniversary, annum, artificial, beneficial, CECL, cent, client, CODM, commencing, concurrent, Corolla, Cosmetic, declared, denial, drafted, entitled, facility, factor, FDCA, Food, footage, forward, governmental, hold, IBR, institutional, intelligence, issuable, lessee, maker, multiplied, participate, participation, pay, percent, premise, prohibited, prohibition, rendered, resale, resolution, separately, Shareholder, shelf, source, square, stem, tenant, threshold, Toyota, transfer, typical, typically, unconsolidated, vehicle, vote, WallachBeth

Removed: accurately, Additionally, adequate, allocate, annuity, began, bridge, calculation, challenge, confirm, conform, converted, created, delivering, detecting, disease, display, distribute, Dougherty, efficient, emergence, enable, evolving, framework, grow, heavily, implement, indeterminate, insight, inventory, July, larger, linkedin, media, Michael, mitigate, operational, ordering, oversight, pandemic, patent, pathway, pivotal, positioning, post, preferentially, present, processing, production, reclassified, refine, reliability, rely, scope, segregation, sensitivity, shipment, social, South, specificity, sputum, step, terminate, trial, usage, viral

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

BIAF similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350

As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of bioAffinity Technologies, Inc., a Delaware Corporation (“Company”), for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (“Report”), each of the undersigned officers of the Company hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of such officer’s knowledge:

	1)	the Report complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of March 31, 2024 (the last date of the period covered by the Report).

	/s/ Maria Zannes
	Maria Zannes
	President and Chief Executive Officer (Principal Executive Officer)
	Date: May 15, 2024

	/s/ Michael Dougherty
	Michael Dougherty
	Vice President and Chief Financial Officer (Principal Financial Officer)
	Date: May 15, 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.